Agios Pharmaceuticals (FRA:8AP) Current Accrued Expense : €11.99 Mil (As of Mar. 2025)

View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals Current Accrued Expense?

Agios Pharmaceuticals's Current Accrued Expense for the quarter that ended in Mar. 2025 was €11.99 Mil.

Agios Pharmaceuticals's quarterly Current Accrued Expense increased from Sep. 2024 (€14.08 Mil) to Dec. 2024 (€16.16 Mil) but then declined from Dec. 2024 (€16.16 Mil) to Mar. 2025 (€11.99 Mil).

Agios Pharmaceuticals's annual Current Accrued Expense increased from Dec. 2022 (€11.56 Mil) to Dec. 2023 (€18.28 Mil) but then declined from Dec. 2023 (€18.28 Mil) to Dec. 2024 (€16.16 Mil).

Agios Pharmaceuticals Current Accrued Expense Historical Data

The historical data trend for Agios Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals Current Accrued Expense Chart

Agios Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

8.60

10.75

11.56

18.28

16.16

Agios Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Current Accrued Expense	Get a 7-Day Free Trial															18.15	23.02	14.08	16.16	11.99

Agios Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Agios Pharmaceuticals Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Agios Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (FRA:8AP) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

AGIO:USA 0HB0:UK 8AP:Germany

Address

88 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.agios.com

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Agios Pharmaceuticals Headlines

No Headlines